The immune system protects the host organism against infectious diseases, principally by eradicating infectious agents. However, pathogen elimination frequently entails collateral tissue damage and inflammation, potentially decreasing host fitness [@R1]. Neuroendocrine-immune interactions play an important role in these regulatory processes, but the mechanisms involved remain unclear [@R2], [@R3]. Endogenous glucocorticoids (cortisol in humans and corticosterone in rodents) are essential steroid hormones that regulate many physiological and developmental processes. They are synthesized in the adrenal cortex upon activation of the hypothalamic--pituitary--adrenal (HPA) axis, a neural-endocrine core for coordinating physiological responses to external stimuli [@R4]. Glucocorticoids released into the blood diffuse through cell membranes to bind cytosolic glucocorticoid receptor (GR), which is ubiquitously expressed and induces changes in gene expression [@R5]. The HPA neuro-endocrine pathway restores homeostasis by limiting and resolving inflammation in many conditions [@R2]. In models of systemic inflammation, such as lipopolysaccharide (LPS)-induced sepsis, glucocorticoids specifically inhibit pro-inflammatory cytokine production in several immune cell-types [@R6], [@R7], [@R8], [@R9].

The HPA axis is also activated during infection with viruses, such as influenza [@R10] and cytomegalovirus (CMV) [@R11]. Murine CMV (MCMV) is a beta herpesvirus used as a model for systemic human CMV infection, which can cause severe disease, especially in immunocompromised patients. Mice rendered glucocorticoid-deficient by adrenalectomy are more susceptible to MCMV-induced death, due to the deleterious effects of cytokine-induced over-inflammation, and resistance is restored by corticosterone replacement [@R12]. Finally, glucocorticoids are clinically effective against many inflammatory and autoimmune diseases [@R13]. In all these conditions, the underlying mechanisms of glucocorticoids remain unclear, because GRs are expressed by many hematopoietic and non-hematopoietic cells and can impact on multiple signaling pathways.

During acute infection, the cytokine interferon- γ (IFN-γ), produced by innate lymphoid cells (ILCs) is essential for antiviral defense [@R14], [@R15], [@R16]. These IFN-γ-producing ILCs include spleen and liver natural killer (NK) cells and liver ILC1s, which all express the GR [@R6]. We investigated here the role of the GR in ILC subsets of relevance during MCMV infection using mice with a conditional deletion of the GR gene in ILCs expressing NCR1, which include NK cells, ILC1s and a subset of ILC3s. We found that endogenous glucocorticoids produced rapidly after infection induced the selective and tissue-specific expression of the immune checkpoint PD-1 on the surface of spleen NK cells. Concomitantly, PD1 ligands were upregulated in several immune cell subsets. PD-1 signalling was required for host survival to infection and acted by limiting the production of IFN-γ by NK in the spleen which prevented immunopathology. This neuroendocrine-immune axis controlled immune tolerance but did not impair viral clearance. Our findings therefore demonstrate a major role for the HPA axis in promoting host resistance to an infectious disease through regulation of the PD-1 inhibitory pathway in an ILC subset.

Results {#S1}
=======

The regulation of NK cell functions by glucocorticoids is organ-specific {#S2}
------------------------------------------------------------------------

During acute infection, MCMV has a high tropism for the spleen and the liver [@R17]. In these organs, NK cells are required for host resistance to infection, and they mediate their anti-viral function through cytokine- and killing-dependent mechanisms [@R18]. Consistent with previous findings [@R11], [@R19], MCMV infection in C57BL/6J wild-type mice induced corticosterone release into the bloodstream, with a peak at 36 h post-infection ([Fig. 1a](#F1){ref-type="fig"}), suggesting that the HPA axis may play a role during the early phase of the infection when NK cells are activated [@R14]. We first analyzed the effect of glucocorticoids on the cytotoxic activity of spleen CD3^-^NCR1^+^ NK cells *in vitro* by stimulating splenocytes isolated from C57BL/6J wild-type mice with antibodies against NK1.1 or PMA and ionomycin. Corticosterone treatment had no effect on degranulation of NK cells, as assessed by measuring CD107a expression ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). We then analyzed the role of the GR pathway in NCR1^+^ ILCs *in vivo* using *Ncr1^iCre/+^Nr3c1^LoxP/LoxP^* mice (hereafter GR^*Ncr1-*iCre^ mice), in which the gene encoding GR (*Nr3c1*) is specifically deleted in NCR1^+^ cells which express the Cre recombinase [@R6], [@R20], [@R21]. Sex matched *Ncr1^iCre/+^* littermates in which the Cre recombinase is expressed in NCR1^+^ cells, but the *Nr3cr1* gene is not deleted, were used throughout as controls (referred to hereafter as WT^*Ncr1-*iCre^), unless otherwise specified. In steady-state conditions, NCR1^+^ ILCs in GR^*Ncr1*-iCre^ mice (i.e. NK cells, ILC1s and a subset of ILC3s) show normal development, maturation and functions [@R6]. We infected GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ littermates with MCMV, and their immune responses were analyzed at 44h post-infection, after blood corticosterone concentration had peaked. The concentrations of corticosterone in the serum were similar in GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ control mice ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). Granzyme B (GrzB), a surrogate marker of NK cell cytotoxicity, was similarly upregulated in NK1.1^+^NCR1^+^DX5^+^CD49a^-^ NK cells from GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ mice, both in spleen and in liver ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"}). In contrast, expression of IFN-γ was higher in spleen GR^*Ncr1*-iCre^ NK cells compared to WT^*Ncr1-*iCre^ control NK cells, as measured by mean fluorescence intensity and in terms of the percentage of IFN-γ^+^ cells ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}). Although corticosterone is known to have a systemic distribution, liver GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ NCR1^+^ NK cells and ILC1s had similar expression of IFN-γ ([Fig. 1c, d](#F1){ref-type="fig"}), suggesting the effect of glucocorticoids was tissue-specific.

Histological analysis of the spleen indicated that GR^*Ncr1*-iCre^ mice had more marked lesions, associated with coalescing and granulomatous necrotic splenitis in the marginal zone compared to WT^*Ncr1-*iCre^ control mice ([Fig. 2a, b](#F2){ref-type="fig"}). In contrast, no significant difference in the nature or extent of the liver lesions was observed between GR^*Ncr1*-iCre^ and control mice, with mild multifocal pyogranulomatous and necrotic hepatitis in both genotypes ([Fig. 2c, d](#F2){ref-type="fig"}). The viral load in the spleen and the liver was similar in GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ mice ([Fig. 2e](#F2){ref-type="fig"}), suggesting that the inflammation-induced tissue damage was not due to an impairment of viral clearance.

NCR1^+^ ILC3s are known to express GR and the GR encoding gene is also deleted in NCR1^+^ ILC3s from GR^*Ncr1*-iCre^ mice [@R6]. These ILC3s are mostly resident in mucosal tissues, where they produce interleukin 22 (IL-22) and IL-17, but not IFN-γ [@R22], and as such they are thought to have minimal involvement in the immune response against MCMV. Nonetheless, we assessed the effect of endogenous glucocorticoids on these cells upon MCMV infection. MCMV infection did not induce an increase in IL-22 and IL-17 production in NCR1^+^ ILC3 from the small intestine in WT^*Ncr1-*iCre^ and GR^*Ncr1*-iCre^ mice ([Supplementary Fig. 2a-d](#SD1){ref-type="supplementary-material"}). The frequency of NCR1^+^ ILC3s in the small intestine was also unaffected ([Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}), suggesting NCR1^+^ ILC3s do not have a major impact on the immune response to MCMV infection. Collectively, these results indicate that responsiveness of NCR1^+^ ILCs to glucocorticoids produced during acute MCMV infection controls spleen inflammation and specifically regulates the production of IFN-γ by spleen NK cells.

Endogenous glucocorticoids induce PD-1 expression on splenic NK cells {#S3}
---------------------------------------------------------------------

Next, we performed RNA-sequencing (RNA-Seq) on spleen CD3^-^CD19^-^NK1.1^+^NCR1^+^DX5^+^ NK cells, liver CD3^-^CD19^-^NK1.1^+^NCR1^+^DX5^+^CD49a^-^ NK cells and liver CD3^-^CD19^-^NK1.1^+^NCR1^+^DX5^-^CD49a^+^ ILC1s sorted from GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ control mice 44h post-infection ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). A pairwise comparison of gene expression between the two genotypes for spleen NK cells, liver NK cells and liver ILC1s identified differentially expressed genes for each ILC subset ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Unsupervised genome-wide analysis indicated that the GR-dependent transcriptomic changes differed between spleen NK cells, liver NK cells and liver ILC1s ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}), suggesting that the regulation of gene expression by glucocorticoids was both organ- and cell lineage-specific *in vivo*. To identify candidate genes associated with the selective hyperinflammation observed in the spleen of GR^*Ncr1-*iCre^ mice, we focused on genes that were differentially expressed between WT^*Ncr1-*iCre^ control and GR^*Ncr1*-iCre^ spleen NK cells ([Fig. 3a](#F3){ref-type="fig"}). In addition to *Nr3c1,* which encodes GR, the expression of *Tsc22d3*, which encodes the glucocorticoid-induced protein GILZ and the expression of *Pdcd1*, which encodes the receptor PD-1 were significantly downregulated in spleen NK cells from GR^*Ncr1*-iCre^ versus WT^*Ncr1-*iCre^ littermates after infection ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

Consistent with the rapid and ubiquitous induction of *Tsc22d3* by glucocorticoids in many cell types and inflammatory conditions [@R23], differential expression of *Tsc22d3* was seen in both spleen and liver NK cells from GR^*Ncr1*-iCre^ versus WT^*Ncr1-*iCre^ mice upon infection ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). GILZ is a mediator of the anti-inflammatory effects of glucocorticoids and regulates survival, homeostasis and apoptosis in various cell types, including lymphoid cells [@R24], [@R25]. We measured NK cell proliferation and apoptosis in the spleen and liver of GR^*Ncr1*-iCre^ mice and littermate controls 44h after infection using Ki67 and AnnexinV/PI flow cytometry staining, respectively. Despite the downregulation of *Tsc22d3* in spleen and liver GR^*Ncr1*-iCre^ NK cells, there was no difference in their level of proliferation and apoptosis compared to WT^*Ncr1-*iCre^ NK cells ([Supplementary Fig. 4 a,b](#SD1){ref-type="supplementary-material"}). Liver ILC1 homeostasis was also similar in WT^*Ncr1-*iCre^ and GR^*Ncr1*-iCre^ mice ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}), suggesting that GILZ does not play a major role in the selective immunopathology observed in the spleen of GR^*Ncr1*-iCre^ mice.

In contrast to *Tsc22d3*, the differential expression of *Pdcd1* was selectively observed in spleen but not liver NK cells from MCMV-infected GR^*Ncr1*-iCre^ mice ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). In addition, *Pdcd1* expression was similar in liver ILC1s from MCMV-infected GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ mice. PD-1 is an inhibitory cell-surface receptor that downregulates T cell activity [@R26]. PD-1 protein was not expressed on the surface of spleen and liver NK cells from uninfected GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ mice, but was detected on splenic NK cells from MCMV-infected WT^*Ncr1-*iCre^ control mice 44h post-infection ([Fig. 3b](#F3){ref-type="fig"}). Importantly, we could not detect PD-1 in spleen NK cells from MCMV-infected GR^*Ncr1-*iCre^ mice ([Fig. 3b](#F3){ref-type="fig"}), showing induction of PD-1 was dependent on the glucocorticoid-GR pathway. PD-1 expression was not detected on spleen macrophages, neutrophils or dendritic cells (DCs) in either non-infected and MCMV-infected wild-type mice 44h post-infection ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). In the spleen of non-infected WT^*Ncr1-*iCre^ and GR^*Ncr1*-iCre^ mice, a discrete subset of T cells (less than 4%) had low basal expression of PD-1, but this T cell subset did not expand and PD-1 expression on T cells did not change upon MCMV infection in either genotypes ([Fig. 3c](#F3){ref-type="fig"}). Expression of PD-1 was not detected on liver NK cells and ILC1 ([Fig. 3d, e](#F3){ref-type="fig"}) consistent with the transcriptomic data. Similar results were obtained using two different clones of anti-PD-1 antibodies (J43 and RMP1-30) ([Fig. 3b](#F3){ref-type="fig"}). These data indicate that glucocorticoids released upon MCMV infection induce the GR-dependent *de-novo* expression of PD-1 on spleen NK cells by regulating *Pdcd1* gene transcription.

NK cell PD-1 expression depends on the cytokine microenvironment {#S4}
----------------------------------------------------------------

Liver NK cells expressed GR both at steady-state [@R6] and upon MCMV infection ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). *Tsc22d3* expression was downregulated similarly in spleen and liver GR^*Ncr1-*iCre^ NK cells compared to corresponding WT^*Ncr1-*iCre^ control cells([Supplementary Table 1](#SD2){ref-type="supplementary-material"}), indicating liver NK cells were responsive to GR signaling. Because the differential expression of PD-1 on liver and spleen NK cells could not be explained by an impaired responsiveness to glucocorticoids, we tested whether it was dependent on the presence of tissue-specific inflammatory cytokines in the microenvironment. We focused on the main cytokines known to modulate NK cell activation. First, RNA from spleen and liver tissue homogenates were extracted from MCMV-infected (44h post-infection) and non-infected wild-type mice and the expression of mRNA for *Il12*, *Il15* and *Il18* was assessed by RT-qPCR. We did not detect any significant difference in *Il18* mRNA expression before and after infection in either organs ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). In contrast, expression of *Il12* mRNA was up-regulated by infection to a greater extent in the liver compared to the spleen, and *Il15* mRNA expression was increased exclusively in the spleen of infected mice compared to un-infected ([Fig. 4a](#F4){ref-type="fig"}). Similar expression patterns for *Il12*, *Il15* and *Il18* were observed in WT^*Ncr1-*iCre^ and GR^*Ncr1-*iCre^ mice (data not shown). These data suggested that the cytokine microenvironment differed between liver and spleen during MCMV infection.

Next we tested whether different combinations of cytokines in the medium modified the effect of GR activation on NK cells *in vitro*. Splenocytes from WT^*Ncr1-*iCre^ and GR^*Ncr1-*iCre^ mice were stimulated for 48h with different combinations of IL-12, IL-15 and IL-18 in the presence or absence of corticosterone. In the absence of corticosterone, PD-1 expression was not induced on CD3^-^NCR1^+^NK1.1^+^ NK cells or CD3^+^ T cells ([Fig. 4b](#F4){ref-type="fig"} and data not shown). Similarly, corticosterone, alone or in combination with IL-15 or with IL-12 and IL-15, did not induce the expression of PD-1 on NK cells or T cells from either genotypes ([Fig. 4b](#F4){ref-type="fig"} and data not shown). In contrast, treatment with corticosterone, IL-15 and IL-18 induced PD-1 expression on NK cells from WT^*Ncr1-*iCre^ control but not from GR^*Ncr1*-iCre^ mice in a dose-dependent manner ([Fig. 4b and c](#F4){ref-type="fig"}). This treatment did not induce the expression of PD-1 on T cells from WT^*Ncr1-*iCre^ or GR^*Ncr1-*iCre^ mice ([Fig.4b](#F4){ref-type="fig"} and data not shown). Addition of IL-12 abolished the corticosterone, IL-15 and IL-18-dependent induction of PD-1 in WT^*Ncr1-*iCre^ control NK cells ([Fig. 4b](#F4){ref-type="fig"}). Similar results were obtained when stimulating NK1.1^+^NCR1^+^ NK cells enriched from splenocytes (86-89% of purity) ([Fig. 4d](#F4){ref-type="fig"} and data not shown), suggesting the effect of IL-15 and IL-18 on NK cells was cell-intrinsic. These data indicated that GR induction of PD-1 was cell type-specific and dependent on NK cell cytokine microenvironment.

The GR-PD-1 axis inhibits IFN-γ production in spleen NK cells {#S5}
-------------------------------------------------------------

The activating NK cell receptor Ly49H mediates resistance to MCMV infection in C57BL/6J mice, by specifically binding the virally encoded protein m157 [@R27]. As such, we investigated the link between expression of PD-1 and Ly49H on spleen NK cells during MCMV infection. Upon infection of wild-type C57BL/6J mice, PD-1 was similarly upregulated on both Ly49H^+^ and Ly49H^-^ spleen NK subsets 44h post-infection ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). Moreover, the frequency of Ly49H^+^ spleen NK cells 5 days post-infection was similar in GR^*Ncr1-*iCre^ and WT^*Ncr1-*iCre^ control mice ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}), suggesting GR signaling and expression of PD-1 did not affect the expansion of the m157-specific NK cells during MCMV infection.

To further investigate whether PD-1 expression and signaling in spleen NK cells may have a functional relevance, we tested whether the PD-1 ligands PD-L1 and PD-L2 were expressed in wild-type mice during MCMV infection. Cytofluorimetric analysis revealed that PD-L1 expression was upregulated on macrophages, DCs, neutrophils, T, B and NK cells from spleen of MCMV-infected compared to non-infected wild-type mice ([Fig. 5a](#F5){ref-type="fig"}), while PD-L2 was expressed only on DCs upon MCMV infection ([Fig. 5b](#F5){ref-type="fig"}). To test whether the potential engagement of PD-1 by its ligands controlled the function of NK cells in the spleen, MCMV infection of GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ control mice was followed by the administration of PD-1 blocking antibodies (PD-1 Ab) or isotype control antibodies (Ig). Antibodies were injected intraperitoneally 1 day post-infection, before the activation of the HPA axis and glucocorticoid release into the bloodstream. At 44h post-infection, the frequency of IFN-γ^+^ splenic NK cells in WT^*Ncr1-*iCre^ mice receiving the PD-1 blockade (about 61%) was higher compared to Ig-injected WT^*Ncr1-*iCre^ mice (about 33 %), but similar to that seen in GR^*Ncr1*-iCre^ mice treated with Ig (54 %) ([Fig. 5c](#F5){ref-type="fig"}). There was no increase in the frequency of IFN-γ^+^ splenic NK cells in GR^*Ncr1*-iCre^ mice receiving the PD-1 blockade compared to Ig-injected mice ([Fig. 5c](#F5){ref-type="fig"}), indicating a strict dependence of the effect of PD-1 on GR-expressing NCR1^+^ NK cells. Moreover, compared to Ig treatment, PD-1 blockade had no effect on the frequency of IFN-γ^+^ NK cells in the liver of WT^*Ncr1-*iCre^ mice ([Fig. 5d](#F5){ref-type="fig"}), consistent with the lack of PD-1 expression on liver NK cells. Thus, during MCMV infection, PD-1 signaling in spleen NK cells limits IFN-γ production by these cells. This regulation occurs in the spleen, but not in the liver.

GR and PD-1 are required for host resistance to MCMV infection {#S6}
--------------------------------------------------------------

To assess the impact of the glucocorticoid-PD1 axis on host resistance to viral infection, we infected 9-10 weeks old GR^*Ncr1*-iCre^ and WT^*Ncr1-*iCre^ control mice with an intraperitoneal median lethal dose (LD50) of MCMV. GR^*Ncr1*-iCre^ mice had a higher mortality (100%) compared to control littermates (62%) ([Fig. 6a](#F6){ref-type="fig"}), indicating that glucocorticoid signaling in NCR1^+^ ILCs was required for host resistance to viral infection. To evaluate the specific contribution of PD-1-PD-1 ligand interaction to host resistance, we infected C57BL/6J wild-type female mice with the LD50 of MCMV, followed by the intraperitoneal administration of PD-1 blocking antibodies or isotype control antibodies 1 day post-infection. All mice receiving PD-1 blocking antibodies succumbed to infection within a week ([Fig. 6b](#F6){ref-type="fig"}), resulting in a mortality similar to that of GR^*Ncr1-*iCre^ mice ([Fig. 6a](#F6){ref-type="fig"}). Importantly, this greater susceptibility to infection was not due to differences in viral replication rates in GR^*Ncr1-*iCre^ mice ([Fig. 6c](#F6){ref-type="fig"}) or in wild-type mice receiving the PD-1 blocking antibody ([Fig. 6d](#F6){ref-type="fig"}) compared to their respective control mice, suggesting the GR-PD-1 regulatory pathway did not impair viral clearance. Wild-type mice receiving anti-PD-1 antibodies presented more marked immunopathological features in the spleen, with larger areas of coalescing necrotic and granulomatous splenitis in the marginal zone compared to wild-type mice receiving control Ig ([Fig. 6e](#F6){ref-type="fig"}). In contrast, hepatic lesion severity was not affected by PD-1 blockade, with both groups of mice displaying moderate-to-marked necrotic and pyogranulomatous hepatitis, with intranuclear inclusions in hepatocytes ([Fig. 6e](#F6){ref-type="fig"}). MCMV-infected wild-type mice treated with anti-PD-1 antibodies were, therefore, phenocopies of the GR^*Ncr1*-iCre^ mice, indicating PD-1 expression mediated the GR-dependent host protection from infection-induced immunopathology.

The GR-PD1-IFN-γ pathway prevents lethal spleen immunopathology {#S7}
---------------------------------------------------------------

PD-1-deficient mice infected with the murine hepatitis virus strain-3 (MHV-3) were reported to have severe spleen and liver damage and high expression of FGL2, a molecule involved in fibrinogen deposition [@R28]. Using RT-qPCR, we found no difference in the expression of *fgl2* in spleen tissue homogenates following Ig injection or PD-1 blockade in MCMV-infected C57BL/6J wild-type mice (data not shown). To further investigate the mechanisms involved in the lethal immunopathological condition in the MCMV-infected GR^*Ncr1*-iCre^ and PD-1 antibody treated mice, we performed cytometric bead array measurement of inflammatory cytokines concentration in serum, spleen and liver upon infection. Three days post-infection, the amounts of IL-6, TNF and IL-10 in the serum and tissues from MCMV-infected GR^*Ncr1*-iCre^ and PD-1 Ab-treated wild-type mice were similar to those seen in WT^*Ncr1-*iCre^ and Ig-treated wild-type mice ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). In contrast, we detected higher IFN-γ production in the spleen and the serum, but not in the liver of MCMV-infected GR^*Ncr1*-iCre^ and PD-1 Ab-treated wild-type mice compared respectively to WT^*Ncr1-*iCre^ and Ig-treated wild-type mice ([Fig. 6 f and g](#F6){ref-type="fig"}). To test whether the NK cell-derived IFN-γ in the spleen of GR^*Ncr1*-iCre^ mice may have a role in spleen hyperinflammation and immunopathology, we treated WT^*Ncr1-*iCre^ and GR^*Ncr1*-iCre^ mice with an IFN-γ blocking antibody or an isotype control (IgG1) on day 1 post-infection, at a time when the HPA axis was activated. Histological analysis revealed marked-to-severe inflammation in the spleen of IgG1-treated GR^*Ncr1*-iCre^ mice on day 3 post-infection, with large and coalescing pyogranulomas and necrotic foci throughout the splenic parenchyma ([Fig. 7a](#F7){ref-type="fig"}). We also observed the destruction of the white pulp, including, in particular, the periarteriolar lymphoid sheath (PALS), which displayed decreased cellularity and atrophy in the severely affected areas and partial replacement by necrotic and granulomatous inflammation ([Fig. 7a](#F7){ref-type="fig"}). Morphometric assessment of the PALS indicated IgG1-treated GR^*Ncr1*-iCre^ mice displayed a more severe destruction of splenic architecture, with a decreased surface of PALS areas on spleen sections than IgG1-treated WT^*Ncr1-*iCre^ mice([Fig. 7b](#F7){ref-type="fig"}). In contrast, GR^*Ncr1*-iCre^ mice treated with the IFN-γ neutralizing antibody showed a rescue of spleen immunopathology to a level similar to that of WT^*Ncr1-*iCre^ mice injected with IgG1 or anti-IFN-γ antibody ([Fig. 7a,b](#F7){ref-type="fig"}). Thus, the glucocorticoids produced upon MCMV infection controlled IFN-γ production by spleen NK cells and IFNγ-mediated spleen immunopathology.

Discussion {#S8}
==========

Here we found that endogenous glucocorticoids produced in response to MCMV infection selectively induced the expression of PD-1 in spleen NK cells, thus controlling their IFN-γ production and preventing the development of a lethal immunopathology in the organ. This regulatory pathway was organ-specific and did not affect viral clearance.

Expression of PD-1 could be induced *in vitro* on NK cells by glucocorticoid treatment in combination with IL-15 and IL-18, and this effect was abolished if IL-12 was also present. Consistent with this, different inflammatory profiles were observed in the spleen and liver of MCMV-infected mice *in vivo*. Although experiments *in vitro* cannot reproduce the complex combination of events occurring in the tissues *in vivo* upon infection, they defined the conditions under which PD-1 can be induced on NK cells. The correlation between the effect of the cytokines *in vitro* and their organ-specific expression *in vivo* suggests that distinct combinations of inflammatory or homeostatic cytokines could cooperate with corticosterone to induce PD-1 expression on NK cells in the spleen. The characterization of the precise inflammatory context involved in the corticosterone-induced regulation of PD-1 expression *in vivo* will require further investigations. For example, PD-1 was expressed on spleen NK cells *in vivo* despite the induction of *Il12* mRNA in this organ. Although we did not measure IL-12 at the protein level, it is possible that different concentrations of recombinant IL-12 *in vitro* and in the NK cell microenvironment *in vivo* mediate different effects. We detected the expression of *Il18* transcripts in the spleen and liver *in vivo*, but not a significant increase in the transcription of this cytokine in both organs at 44h post-infection. However, as IL-18 is synthesized as an inactive precursor requiring proteolytic cleavage to produce the biologically active cytokine [@R29], it is possible that expression of the mature IL-18 protein is regulated at the tissue level. In line with this, expression of mature IL-18 has been reported to be higher in the spleen than in the liver after MCMV infection [@R30], providing a possible explanation for the organ-specific induction of PD-1 on spleen NK cells.

In the hematopoietic lineage, the regulation of PD-1 expression by glucocorticoids during the early stage of MCMV infection appears restricted to NK cells. It would be interesting to determine whether endogenous glucocorticoids induce PD-1 expression on various immune cells, including T cells, in other pathological contexts, as PD-1 expression has been reported on several immune cell subsets in other models of viral infection [@R28], [@R31], [@R32]. PD-1 is upregulated on T cells during various conditions of activation [@R26]. The lack of PD-1 induction on T cells early in MCMV infection observed here is expected, as T lymphocytes are activated during the later phase of the infection [@R17]. Moreover, treatment with different combinations of inflammatory cytokines and corticosterone *in vitro* did not induce PD-1 expression on T cells. Thus, GR-induced PD-1 regulation is specific for NK cells.

We showed that GR-dependent PD-1 induction on spleen NK cells was required to control the production of IFN-γ in these cells, thereby preventing IFN-γ-dependent immunopathology in the spleen. However, the viral loads were similar in the spleens of wild-type and GR^*Ncr1*-iCre^ mice, indicating that the downregulation of IFN-γ production by the HPA axis did not compromise the control of viral replication. Similarly, PD-1 blockade in wild-type mice phenocopied the spleen hyperinflammation seen in GR^*Ncr1*-iCre^ mice, and it did not modify the viral load. Consistent with these results, previous studies have shown that splenic NK cells exert their antiviral effects in a perforin-dependent manner, suggesting a major role for cytotoxic mechanisms in this organ [@R33]. GR activation had no effect on the cytotoxic activity of NK cells, suggesting a decoupling between the actions of glucocorticoids on the main antiviral functions of NK cells. In the liver, IFN-γ production by NK cells is a major mechanism for the control of MCMV replication [@R15], [@R33], [@R34]. Despite high concentrations of corticosterone in the serum, PD-1 was not upregulated in liver NK cells, and the IFN-γ production of these cells was unaffected. Therefore, the dampening of NK cell functions by the HPA axis does not affect the effectiveness of the anti-viral response in both the spleen and liver.

The glucocorticoid-dependent induction of PD-1 expression on NK cells in MCMV infection is a previously unrecognized mechanism by which the HPA axis suppresses immunopathology and promotes disease resistance without compromising protective immunity. It will be important to evaluate the role of this pathway in other infectious conditions or in patients with inflammatory diseases. Along this line, a population of PD-1^+^ NK cells has been identified in healthy donors seropositive for HCMV [@R35], in HIV-1-seropositive individuals [@R36] and in patients with Kaposi sarcoma [@R37], but the mechanisms of regulation of PD-1 expression on these cells remain to be addressed. It will be also interesting to analyze whether PD-1 expression on immune cells is associated with the immune dysfunctions observed in patients in other conditions in which the HPA axis is activated, such as psychological distress and tissue damage [@R38].

Novel immunotherapies acting through the blockade of immune checkpoints, such as PD-1, have yielded outstanding results for advanced cancers [@R39], [@R40]. In cancer patients, inflammatory reactions can be managed with immunosuppressive agents, such as corticosteroids [@R39]. It will be important to determine in which conditions and on which cells PD-1 expression can be induced by these treatments. This analysis could make it possible to identify new pathological situations in which treatment with PD-1 antibodies could be effective. A deeper understanding of the physiological and pathological conditions in which this glucocorticoid-PD-1 pathway exerts some beneficial or detrimental effects could provide rational basis for the development of new therapeutic strategies.

Methods {#S9}
=======

Mice {#S10}
----

Female mice on a C57BL/6 background were used in this study. Wild-type C57BL/6J mice were purchased from Janvier Labs. *Ncr1^iCre/+^Nr3c1^LoxP/LoxP^* (GR^*Ncr1-iCre*^) mice were generated as previously described [@R6]. Sex mtched *Ncr1^iCre/+^* littermate (WT^*Ncr1-*iCre^) were used as controls for GR^*Ncr1-iCre*^ mice. In some experiments in which 2 to 5 mice per genotype per experimental condition were analyzed, mice from several litters were used. All the mice used were bred and maintained under specific pathogen-free conditions at the *Centre d'Immunophenomique (Ciphe) de Marseille* and the *Centre d'Immunologie de Marseille Luminy*. Mice were housed under a standard 12 h:12 h light-dark cycle with *ad libitum* access to food and water. Age-matched (7-10 weeks old) and sex-matched littermate mice were used as controls. All experiments were conducted in accordance with institutional committee recommendations (Comité d\'Ethique de Marseille n°14 - APAFiS \#14260) and French and European guidelines for animal care.

MCMV infection {#S11}
--------------

Stocks of Smith strain MCMV were generated by homogenizing salivary glands harvested from six-week-old BALB/c mice infected with 2.5 x 10^3^ PFU of MCMV at the age of three weeks. Mice were infected at 2 p.m., by the ip injection of 10^3^ PFU/g or 3 x 10^3^ PFU/g (LD50) MCMV diluted in DMEM. "Non-infected" (NI) mice received DMEM only. For PD-1 blockade experiments, 250 μg anti-PD-1 Ab (clone J43 or RMP1-14) or the appropriate isotype control Ab (Armenian Hamster IgG or IgG2a mAb clone 2A3) (all from BioXCell) were injected i.p. into mice on day 1 PI. For IFN-γ neutralization, 500 μg anti-IFNγ Ab (clone XMG1.2) or Rat IgG1 (HRPN) (both from BioXCell) were injected i.p. into mice on day 1 PI. Spleens and livers were harvested after perfusion at different time points, and were processed for FACS or histology analysis, or weighed and homogenized for RNA or protein extraction. Organs were homogenized in a FastPrep-24™ 5G homogenizer (MP Biomedicals).

Viral titer and q-RT-PCR {#S12}
------------------------

Organs were kept in RNAlater (Qiagen) after harvesting. RNA was extracted from organ homogenates with the RNeasy Fibrous Tissue Mini Kit (Qiagen), and reverse-transcribed with the iScript cDNA Synthesis kit (Biorad). Viral titers were determined, by qPCR, as absolute levels of the *Ie1* gene (F: 5'GAGTCTGGAACCGAAACCGT3'; R: 5'GTCGCTGTTATCATTCCCCAC3', Sigma) using the SYBR Green Master Mix (Takara). For *Il15*, *Il12* and *Il18* gene expression analysis, microfluidic quantitative real-time RT-PCR with the Biomark HD system (Fluidigm) was used. Briefly, pre-amplified cDNA (22 cycles) was diluted fivefold before analysis in a Flex Six IFC (Fluidigm) with Universal PCR Master Mix (Fluidigm) and ready-to-use primer and probe sets pre-developed by Applied Biosystems (TaqMan Gene Expression Assays): IL-15 (Mm00434226_m1), IL-12b (Mm00434174_m1), IL-18 (Mm00434226_m1) and GAPDH as a housekeeper (Mm99999915_g1). Ct values were calculated from the system's software (BioMark Real-time PCR Analysis; Fluidigm).

In vitro splenocytes stimulation {#S13}
--------------------------------

Total splenocytes or spleen NK cells (enriched with the NK cell isolation kit from Miltenyi Biotech) from WT^*Ncr1*-iCre^ and GR^*Ncr1-i*Cre^ mice were stimulated *in vitro* in complete culture medium (RPMI 10% FCS, 100 μg/ml penicillin/streptomycin, 2 mM l-glutamine, 1 mM sodium pyruvate, and 0.01 M Hepes) with: 25 ng/ml IL-12 (eBiosciences), 25 ng/ml IL-15 (Peprotech) and 20 ng/ml IL-18 (MBL) alone or in combination, or with PMA (200ng/ml, Sigma) and ionomycin (1μg/ml, Sigma). For NK1.1 stimulation 96 well plates (Immulon 2HB) were coated overnight at 37°C with 2.5 μl/well anti-NK1.1 Ab (PK136, eBiosciences) or IgG2a isotype control before cell plating. During stimulation, 250 or 500 nM corticosterone (Sigma; dissolved in ethanol) or the same volume of vehicle alone were added to the medium. Cells were stimulated at 37°C in the presence of Golgi Stop and Golgi Plug from BD Biosciences, and then washed and stained for FACS analysis. For CD107a staining, 2.5 μl/well of anti-CD107a-FITC antibody (1D4B, BD Biosciences) were added during stimulation.

Cytokine levels in tissues {#S14}
--------------------------

We determined IFN-γ, IL-6, TNF and IL-10 protein levels in organ homogenates with cytometric bead arrays, according to the manufacturer's protocol (CBA, BD Biosciences). Results obtained in pg/ml were converted to μg or ng/mg of tissue considering the weight of the organ before homogenization.

Serum analysis {#S15}
--------------

Blood was collected from the retro-orbital sinus of MCMV-infected mice under low-stress conditions (i.e., within 2 min of handling). After blood coagulation at room temperature, blood samples were centrifugated to separate the serum from the cloth. Serum samples were analyzed with the Corticosterone ELISA Kit (Enzo), according to the manufacturer's instructions, to determine corticosterone concentration, or were analysed with the cytometric bead arrays, according to the manufacturer's protocol (CBA, BD Biosciences), to determine cytokines concentration.

Flow cytometry {#S16}
--------------

Single-cell suspensions were obtained from the spleen by scratching it through 70μm cell strainer, or from the liver by scratching it through 100μm cell strainer and subsequent lymphocyte isolation on a 37.5%-67.5% Percoll gradient. For isolation of small intestine lamina propria cells, intestines were cut longitudinally, then transversally in 2-3cm pieces, thoroughly rinsed with PBS, and shaken for 30 minutes in PBS containing 10% FBS, 15mM Hepes and 5mM EDTA to remove intraepithelial and epithelial cells. Intestines were then digested with collagenase VIII (300UI/mL; Sigma) in complete RPMI for 45 minutes at 37°C under agitation, and lamina propria lymphocytes were isolated on a 40%-100% Percoll gradient. Cells were incubated with the Fc blocking antibody (2.4G2) and with a fixable blue dead-cell stain kit (Invitrogen). Surface molecules were stained with antibodies against: CD45.2 Alexa Fluor 700 (104), CD3 PE-CF594 and APC/Cy7 (145-2C11), CD19 PE-CF594 (1D3), NK1.1 BV510 (PK136), CD49a Alexa Fluor 647 (Ha31/8), CD11b BV510 (M1/70), MHCII BV605 (M5/114.15.2), TCRb FITC (H57-597), PD-1 BV650 (J43, and Hamster IgG2 isotype control), PDL1 PE (MIH5) from BD Biosciences; NKp46 PerCP-eFluor 710 and PE/Cy7 (29A1.4), CD49b PE/Cy7 (DX5), F4/80 APC (BM8), Ly49H APC (3D10) from eBioscience; CD11c PE/Cy7 (N418), CD19 APC/Cy7 (6D5), PD-1 PE (RMP1-30, and Rat IgG2b isotype control), PDL2 PE (TY25) and Ly6G APC/Cy7 (1A8) from Biolegend. For intracellular staining, cells were fixed and permeabilized with an intracellular staining kit (eBioscience), and the following antibodies were used: anti-IFN-γ BV421 (XMG1.2) from Biolegend; anti-granzyme B PE (GB11), anti-Rorγt PE-CF594 (Q31-378), anti-IL17 PE (TC11-18H10), anti-Ki67 PE (B56) from BD Biosciences, anti-IL-22 (JOP eBioscience, coupled to Alexa Fluor 647 with an antibody labeling kit from Life Technologies), anti-GR Alexa Fluor 488 XP rabbit mAb (D8H2) and rabbit mAb IgG Alexa Fluor 488 XP (DA1E) from Cell Signaling Technology. Stained samples were analyzed in a BD LSRII flow cytometer (BD Biosciences). Apoptosis was detected with the FITC Annexin V Apoptosis Detection Kit I from BD Biosciences, according to the manufacturer's protocol.

Gating strategy is shown for each population in the [supplementary information](#SM){ref-type="supplementary-material"}.

Histology {#S17}
---------

Tissues were fixed in 10% neutral buffered formalin for 24h, dehydrated and embedded in paraffin. Sections of 3.5 μm were cut using the microtome Leica RM2245. Hematoxylin-eosin (H&E) staining was effectuated automatically with Leica autostainer XL and slides were mounted with entellan and kept at room temperature. Histological slides of spleen and liver tissue were assessed by an anatomopathologist in a blinded way. For spleen inflammation grading, a score was assigned based on the severity: 0 for normal spleen, 1 for mild (multifocal pyogranulomas in marginal zones), 2 for moderate (locally coalescing pyogranulomas in marginal zones with small necrotic foci), 3 for marked (large and coalescing pyogranulomas throughout the splenic parenchyma with extensive necrotic foci, PALS are preserved), and 4 for severe (extensive necrotic and pyogranulomatous foci, PALS are partially replaced by necrotic and granulomatous inflammation). For liver inflammation grading, a score was assigned based on the severity: 0 for normal, 1 for mild (multifocal pyogranulomatous hepatitis with scattered single necrotic hepatocytes), 2 for moderate (multifocal to coalescing necrotic and pyogranulomatous hepatitis with intranuclear inclusions in hepatocytes), and 3 for marked (coalescing necrotic and pyogranulomatous hepatitis with intranuclear inclusions in hepatocytes). For the morphometric assessment of periarteriolar lymphoid sheath (PALS), the area of PALS and the total area of spleen section were measured using the CaseViewer software from 3Dhistech. Analysis was done on pictures taken with a Nikon Eclipse Ci microscope, on random cross sections of the spleens.

Cell sorting and mRNAseq analysis {#S18}
---------------------------------

Splenocytes (after NK cell enrichment with the mouse NK Cell Isolation Kit II, Miltenyi Biotec) and liver lymphocytes were pooled from three mice for each genotype. A FACS Aria III (BD Biosciences) was used to sort approximately 5 x 10^5^ NK cells from the spleen and liver and 5 x 10^4^ liver-resident ILC1s. Cells were sorted directly in RLT lysis buffer (Qiagen). Total RNA was prepared from purified ILC populations with an RNeasy Micro Kit (Qiagen). Three biological replicates were generated for all samples except for the GR^*Ncr1*-iCre^ liver ILC1s sample (two biological replicates). Preamplification was performed with the SMART-Seq® v4 Ultra® Low-Input RNA Kit (Clontech). The DNA libraries were generated by double-indexing with the Nextera XT DNA Kit (Illumina) and RNA sequencing was performed with a NextSeq 500 (Illumina; paired-end reads 2x75 with 30 M reads per sample). The fastq files were assessed with the fastqc program and trimming was performed with Trimmomatics, to remove potential molecular barcodes, Illumina adapters and low-quality reads. Alignment was performed with two algorithms: firstly, with bowtie2 vs GRCm38 ensemble transcriptome resulting in a BAM that could be processed with the molecular index provided by the kit vendor, and, secondly, with HiSat2 over the GRCm38 genome, for the detection of novel junction regions. Duplicates were detected and removed by MarkDuplicates from picard tools, and the number of reads mapped to each gene was determined with featureCounts v1.5.2. Normalization and differential analysis were performed with DESeq2 v1.16.1. HalioDx (Marseille, France) processed the RNA samples and bioinformatics analyses were performed by the CIML platform.

Statistical analysis {#S19}
--------------------

No sample size calculation was performed, but a reasonable sample size was chosen to ensure adequate reproducibility of results and was based on our previous studies. Mice were assigned to experimental groups according to sex and age. Statistical analysis was performed with Graphpad Prism 7 Software. Normality was tested with the Shapiro-Wilk test. Unpaired two-tailed Student's t-tests were used if the data followed a Gaussian distribution with similar variances. Mann-Whitney U tests were performed if this was not the case. One-way ANOVA was used for multigroup comparisons. Differences in survival were evaluated with Mantel-Cox tests. Differences were considered significant for P values less than 0.05.

Reporting Summary {#S20}
-----------------

Further information on experimental design is available in the Nature Research [Reporting Summary](#SD3){ref-type="supplementary-material"} linked to this article.
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![Organ-specific glucocorticoid regulation of NCR1+ ILCs IFN- γ production in spleen and liver upon MCMV infection.\
**a**, ELISA showing corticosterone concentration in the serum of WT mice receiving injections of MCMV (*n*=5) or DMEM (NI, non-infected) (*n*=5), pool of 2 experiments. Means ± s.e.m., \**P*\<0.05, \*\**P*\<0.01, \*\*\*\**P*\<0.0001, one-way ANOVA. **b-d**, FACS analysis of intracellular IFN-γ, assessed directly *ex vivo* without *in vitro* re-stimulation. Frequencies of IFN-γ-producing spleen NK cells (**b**, *n*=10 NI, *n*=16 WT^*Ncr1*-iCre^ MCMV, or *n*=15 GR^*Ncr1*-iCre^ MCMV mice; pool of 5 experiments), liver NK cells (**c**, *n*=10 NI, *n*=16 WT^*Ncr1*-iCre^ MCMV, or *n*=15 GR^*Ncr1*-iCre^ MCMV mice; pool of 5 experiments) and liver ILC1s (**d**, *n*=9 WT^*Ncr1*-iCre^ NI, *n*=11 GR^*Ncr1*-iCre^ NI, *n*=16 WT^*Ncr1*-iCre^ MCMV, or *n*=15 GR^*Ncr1*-iCre^ MCMV mice; pool of 5 experiments) 44 h post-infection (PI) are shown as means ± s.e.m. and representative FACS plots. \**P*\<0.05, two-tailed Student's *t*-test. Every symbol in b-d represents a single mouse.](emss-78732-f001){#F1}

![GR^*Ncr1-*iCre^ mice display more marked inflammation in the spleen than WT^*Ncr1*-iCre^ mice but their viral titer is unaffected.\
Histology (H&E staining) of spleen (**a**) and liver (**c**) 44 h PI. Representative images of 8 mice per genotype from 2 experiments are shown. The arrowheads in **a** indicate the inflammation area in the marginal zone. The bar represents 50 μm. **b** and **d**, histopathological quantification of spleen (**b**) and liver (**d**) inflammation: 1=mild, 2=moderate and 3=marked. *n*=7 (WT^*Ncr1*-iCre^) and *n*=9 (GR^*Ncr1*-iCre^) mice, pool of 2 experiments. Means ± s.e.m., \**P*\<0.05, two-tailed Mann-Whitney test. **e**, qPCR absolute quantification of viral titer at 44 h PI. *n* =7 (WT^*Ncr1*-iCre^) and *n*=8 (GR^*Ncr1*-iCre^) mice; pool of 2 experiments. Means ± s.e.m.. Every symbol in **b**, **d** and **e** represents a single mouse.](emss-78732-f002){#F2}

![MCMV infection induces glucocorticoid-dependent PD-1 expression in spleen NK cells.\
**a**. RNA Seq analysis. MA plot of genes differentially expressed between spleen NK cells sorted from GR^*Ncr1*-iCre^ and WT^*Ncr1*-iCre^l mice 44 h PI. Genes with significantly lower (red) levels of expression in GR-deficient NK cells are highlighted (absolute log~2~ fold-change\>1 and *P*\<0.05). *n*=3 samples GR^*Ncr1*-iCre^ versus 3 WT^*Ncr1*-iCre^samples. **b**-**e** FACS analysis of cell surface PD-1 expression in spleen NK cells (**b,** *n*=6 NI, *n*=9 WT^*Ncr1*-iCre^ MCMV and *n*=12 GR^*Ncr1*-iCre^ MCMV mice; pool of 3 experiments), spleen T cells (**c,** *n*=2 NI, *n*=4 WT^*Ncr1*-iCre^ MCMV and *n*=6 GR^*Ncr1*-iCre^ MCMV mice; pool of 2 experiments), liver NK cells (**d**, *n*=3 NI, *n*=7 WT^*Ncr1*-iCre^ MCMV and *n*=8 GR^*Ncr1*-iCre^ MCMV mice; pool of 2 experiments) and liver ILC1s (**e**, *n*=2 NI, *n*=4 WT^*Ncr1*-iCre^ MCMV and *n*=6 GR^*Ncr1*-iCre^ MCMV mice; pool of 2 experiments) 44h PI shown as MFI (mean fluorescence intensity) ratio relative to isotype control. Means ± s.e.m., \*\**P*\<0.01, one-way ANOVA. Similar results were obtained using two different anti-PD-1 antibodies (J43 and RMP1-30). Every symbol in **b**-**e** represents a single mouse.](emss-78732-f003){#F3}

![Specific combinations of cytokines and corticosterone cooperate to induce PD-1 expression on NK cells.\
**a**, qRT-PCR for *Il12* and *Il15* from RNA extracted from WT mice spleen and liver homogenates 44h PI. *n*=7, pool of 2 experiments. Each symbol represents a single mouse. Mean, \**P*\<0.05*, \*\*P*\<0.01, ns=not significant, two-tailed Mann-Whitney test. **b**-**d**, FACS analysis of PD-1 expression after *in vitro* stimulation for 48h at 37°C with the indicated combinations of cytokines, in the presence of corticosterone or vehicle alone: total splenocytes (**b** and **c**) and purified spleen NK cells (**d**) from WT^*Ncr1*-iCre^ and GR^*Ncr1*-iCre^ mice were used. In **d**, the frequency of NK cells among live cells was between 86 and 89% as shown in the cytometry plots. **b**, *n*=3 independent experiments (vehicle and Cort 500nM treated NK GR^+^ and T cells stimulated with IL-12+IL15, IL-15+IL-18 and IL-12+IL-15+IL-18 samples) and *n*=2 independent experiments (all the other samples). \**P*\<0.05, one-way ANOVA. Means ± s.d. and representative FACS plots of IL-15 + IL-18 stimulation (**c** and **d**) are shown. Every symbol in **b** represents a single experiment.](emss-78732-f004){#F4}

![MCMV-induced IFN-γ production by spleen NK cells is regulated by a glucocorticoid-PD-1 axis.\
**a** and **b,** FACS analysis of cell surface PDL1 (**a**) and PDL2 (**b**) expression 44 h PI by macrophages (CD11c^-^CD11b^+^F4/80^+^), DCs (CD11c^+^MHCIIhi), neutrophils (CD11c^-^CD11b^+^Ly6G^+^), NK cells (NK1.1^+^NKp46^+^CD49b^+^), B cells (CD19^+^) and T cells (CD3^+^NK1.1^-^) in the spleen (*n*=2 independent experiments). **c** and **d**, FACS analysis of intracellular IFN-γ, assessed directly *ex vivo* without *in vitro* restimulation. Frequency of IFN-γ--producing NK cells in the spleen (**c**) and liver (**d**) 44 h PI, following treatment with an anti-PD-1 antibody or an isotype control antibody (Ig). **c,** *n*=8 (WT^*Ncr1*-iCre^ Ig and PD-1 Ab), *n*=6 (GR^*Ncr1*-iCre^ Ig), and *n* =7 (GR^*Ncr1*-iCre^ PD-1 Ab) mice; pool of 4 experiments. **d,** *n*=9 (Ig) and *n*=7 (PD-1 Ab) mice; pool of 4 experiments. Means ± s.e.m. and representative FACS plots. \**P*\<0.05, one-way ANOVA. Every symbol represents a single mouse.](emss-78732-f005){#F5}

![The glucocorticoid-PD-1 regulatory pathway is required for protection against MCMV infection.\
(**a)** Survival curve for mice infected with MCMV (*n*=13, pool of 3 experiments), and (**b**) receiving injections of anti-PD-1 or an isotype control antibody (Ig). *n*=11 (Ig) and *n*=10 (PD-1 Ab), pool of 2 experiments. \*\**P*\<0.01**,** two-tailed log-rank Mantel-Cox test. **c** and **d**, qPCR absolute quantification of viral titer 3 days PI. **c**, *n*=6 (WT^*Ncr1*-iCre^) and *n*=9 (GR^*Ncr1*-iCre^) mice, pool of 2 experiments. **d**, *n*=9 (Ig) and *n*=10 (PD-1 Ab) mice, pool of 2 experiments. **e**, Histology (H&E staining) of spleen and liver 3 days PI. For each panel, a higher magnification of the corresponding areas in the black boxes is shown. The bar represents 100 μm. Similar results were obtained with two different anti-PD-1 antibody clones (J43 and RMP1-14). *n* =4 (Ig) and *n*=5 (PD-1 Ab) mice. **f** and **g**, cytometric bead array measurement of IFN-γ concentration 3 days PI. **f**, *n*=7 (serum WT^*Ncr1*-iCre^), *n*=8 (serum GR^*Ncr1*-iCre^ and WT^*Ncr1*-iCre^ spleen and liver), and *n*=14 (GR^*Ncr1*-iCre^ spleen and liver) mice; pool of 2 experiments (serum) and pool of 3 experiments (spleen and liver). \*P\<0.05, two-tailed Mann-Whitney test (serum) and two-tailed Student's t-test (spleen). **g**, *n*=7 (Ig serum), *n*=8 (PD-1 Ab serum), and *n*=9 (spleen and liver) mice; pool of 2 experiments. \*\*P\<0.01, two-tailed Mann-Whitney test (serum) and \*P\<0.05, two-tailed Student's t-test (spleen). Means ± s.e.m. are shown for **c**, **d**, **f** and **g**. Each symbol represents a single mouse.](emss-78732-f006){#F6}

![IFN-γ neutralization prevents spleen immunopathology in GR^*Ncr1-*iCre^ mice.\
Histology (H&E staining) of the spleen 3 days PI. Mice were infected with the LD50 of MCMV and injected on day 1 PI with anti-IFNγ or IgG1 isotype control antibodies. The bar represents 500 μm. **b**, histopathological quantification of spleen inflammation: the area covered by PALS was measured and expressed as percentage of the total area of the spleen section. *n*=10 (WT^*Ncr1*-iCre^ IgG1), *n*=9 (GR^*Ncr1*-iCre^ IgG1), *n*=11 (WT^*Ncr1*-iCre^ IFN-γ Ab), and *n*=5 (GR^*Ncr1*-iCre^ IFN-γ Ab) mice; pool of 2 experiments. \**P*\<0.05, one-way ANOVA, ns=not significant. Means ± s.e.m.. Each symbol represents a single mouse.](emss-78732-f007){#F7}
